???global.info.a_carregar???
Identification

Personal identification

Full name
Jocelyne Demengeot

Author identifiers

Ciência ID
3A12-B260-A36C
ORCID iD
0000-0002-4761-614X
Outputs

Publications

Book
  1. Garcês, S.; Demengeot, J.; Demengeot, Jocelyne. The Immunogenicity of Biologic Therapies. 2017.
    10.1159/000478077
Book chapter
  1. da Silva Domingues, Vital; Caramalho, Iris; Bergman, Marie-Louise; Demengeot, Jocelyne. Corresponding author: Demengeot, Jocelyne. "Adoptive Transfer and Bone Marrow Chimera Models to Analyze Treg Function and Differentiation". In Methods in Molecular Biology, 15-29. Springer US, 2023.
    10.1007/978-1-0716-2647-4_2
  2. Garcês, Sandra; Demengeot, Jocelyne. "The Immunogenicity of Biologic Therapies". In Current Problems in Dermatology, 37-48. S. Karger AG, 2017.
    10.1159/000478077
  3. Hori, Shohei; Demengeot, Jocelyne; Bandeira, Antonio; Coutinho, Antonio. "Cancer Immunity: A Problem of Self-Tolerance". In Cancer and Autoimmunity, 337-342. Elsevier, 2000.
    10.1016/b978-044450331-2/50035-7
Journal article
  1. Qian Wu; Carlos, A R; Faouzi Braza; Marie-Louise Bergman; Jamil Kitoko; Patricia Bastos Amador; Eloy Cuadrado; et al. "Ferritin heavy chain supports stability and function of the regulatory T cell lineage". The EMBO Journal (2024): http://dx.doi.org/10.1038/s44318-024-00064-x.
    10.1038/s44318-024-00064-x
  2. Caramalho, Iris; Matoso, Paula; Ligeiro, Dário; Paixão, Tiago; Sobral, Daniel; Fitas, Ana Laura; Limbert, Catarina; Demengeot, Jocelyne; Penha-Gonçalves, Carlos. Corresponding author: Caramalho, Iris. "The rare DRB1*04:08-DQ8 haplotype is the main HLA class II genetic driver and discriminative factor of Early-onset Type 1 diabetes in the Portuguese population". Frontiers in Immunology 14 (2024): http://dx.doi.org/10.3389/fimmu.2023.1299609.
    10.3389/fimmu.2023.1299609
  3. Meehan, T.F.; Chen, C.-K.; Koscielny, G.; Relac, M.; Wilkinson, P.; Flicek, P.; Parkinson, H.; et al. "INFRAFRONTIER-providing mutant mouse resources as research tools for the international scientific community". Nucleic Acids Research 43 D1 (2015): D1171-D1175. http://www.scopus.com/inward/record.url?eid=2-s2.0-84941108631&partnerID=MN8TOARS.
    10.1093/nar/gku1193
  4. S Garcês; M Antunes; E Benito-Garcia; J Canas-Silva; L Aarden; J Demengeot. "A1.79 A preliminary algorithm introducing immunogenicity assessment in the management of RA patients receiving biotechnological therapies". Annals of the Rheumatic Diseases 73 Suppl 1 (2014): A35.1-A35. https://doi.org/10.1136%2Fannrheumdis-2013-205124.78.
    10.1136/annrheumdis-2013-205124.78
  5. S. Garcês; J. Canas-da-Silva; L. Aarden; J. Demengeot. "FRI0092 New algorithm to approach ra patients receiving biologic therapies: Introducing immunogenicity assessment in the eular guidelines". Annals of the Rheumatic Diseases 71 Suppl 3 (2014): 340.2-340. https://doi.org/10.1136%2Fannrheumdis-2012-eular.2549.
    10.1136/annrheumdis-2012-eular.2549
  6. S. Garcês; J. Demengeot; J. Canas-da-Silva; L. Aarden. "AB1297 Bridging ELISA as a secreening assay to monitor immunogenicity in routine clinical practice". Annals of the Rheumatic Diseases 71 Suppl 3 (2014): 711.17-711. https://doi.org/10.1136%2Fannrheumdis-2012-eular.1293.
    10.1136/annrheumdis-2012-eular.1293
  7. S. Garcês; J. Freitas; J. Canas-Silva; L. Aarden; J. Demengeot. "FRI0188 The impact of immunogenicity on drug safety profile". Annals of the Rheumatic Diseases 72 Suppl 3 (2014): A436.1-A436. https://doi.org/10.1136%2Fannrheumdis-2013-eular.1315.
    10.1136/annrheumdis-2013-eular.1315
  8. S. Garcês; M. Antunes; E. Benito-Garcia; J. Canas-Silva; L. Aarden; J. Demengeot. "FRI0189 A preliminary algorithm introducing immunogenicity assessment in the management of ra patients receiving biotechnological therapies". Annals of the Rheumatic Diseases 72 Suppl 3 (2014): A436.2-A436. https://doi.org/10.1136%2Fannrheumdis-2013-eular.1316.
    10.1136/annrheumdis-2013-eular.1316
  9. S. Garcês; J. Demengeot; E. Benito-Garcia. "SAT0479 Clinical impact of immunogenicity of infliximab, adalimumab and etanercept: A systematic review of the literature with a meta-analysis". Annals of the Rheumatic Diseases 71 Suppl 3 (2014): 634.3-635. https://doi.org/10.1136%2Fannrheumdis-2012-eular.3425.
    10.1136/annrheumdis-2012-eular.3425
  10. Mathieu, C.; Overbergh, L.; Badenhoop, K.; Bingley, P.J.; Dayan, C.M.; Demengeot, J.; Dotta, F.; et al. "The story of NAIMIT - A framework 7 project on type 1 diabetes". European Endocrinology 10 2 (2014): 100-105. http://www.scopus.com/inward/record.url?eid=2-s2.0-84920275834&partnerID=MN8TOARS.
  11. Carneiro, J.; Leon, K.; Caramalho, Í.; Van Den Dool, C.; Gardner, R.; Oliveira, V.; Bergman, M.-L.; et al. "When three is not a crowd: A Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+T cells". Immunological Reviews 216 1 (2007): 48-68. http://www.scopus.com/inward/record.url?eid=2-s2.0-33947192440&partnerID=MN8TOARS.
    10.1111/j.1600-065X.2007.00487.x
  12. Zelenay, S.; Demengeot, J.; Zelenay, Santiago; Demengeot, Jocelyne. "Comment on "Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4 +CD25+ T regulatory cells" [4]". Journal of Immunology 177 4 (2006): 2036-2037. http://www.scopus.com/inward/record.url?eid=2-s2.0-33746879581&partnerID=MN8TOARS.
    10.4049/jimmunol.177.4.2036-a
  13. Coutinho A; Caramalho I; Seixas E; Demengeot J; Coutinho, A.; Caramalho, I.; Seixas, E.; Demengeot, Jocelyne; Demengeot, J.. "Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.". Current topics in microbiology and immunology 293 (2005): http://europepmc.org/abstract/med/15981475.
    Published • 10.1007/3-540-27702-1_3
  14. Braun, D.; Geraldes, P.; Demengeot, J.; Braun, D. "Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice". Journal of Autoimmunity 20 1 (2003): 15-25. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037320208&partnerID=MN8TOARS.
    10.1016/S0896-8411(02)00109-9
  15. Demengeot, J.; Hori, S.. "Keeping hopes high. Workshop on the molecular and genetic basis of autoimmune diseases: SLE and RA". EMBO Reports 4 11 (2003): 1033-1037. http://www.scopus.com/inward/record.url?eid=2-s2.0-0346873030&partnerID=MN8TOARS.
    10.1038/sj.embor.7400012
  16. Hori, S.; Carvalho, T.L.; Demengeot, J.; Hori, Shohei; Carvalho, Thiago L.; Demengeot, Jocelyne. "CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice". European Journal of Immunology 32 5 (2002): 1282-1291. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036107373&partnerID=MN8TOARS.
    10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#
  17. Braun, D.; Caramalho, I.; Demengeot, J.; Braun, Déborah; Caramalho, Iris; Demengeot, Jocelyne. "IFn-a/ß enhances BCR-dependent B cell responses". International Immunology 14 4 (2002): 411-419. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036206908&partnerID=MN8TOARS.
    10.1093/intimm/14.4.411
  18. Taccioli, G.E.; Gottlieb, T.M.; Blunt, T.; Priestley, A.; Demengeot, J.; Mizuta, R.; Lehmann, A.R.; et al. "Ku80: Product of the XRCC5 gene and its role in DNA repair and V(D)J recombination". Science 265 5177 (1994): 1442-1445. http://www.scopus.com/inward/record.url?eid=2-s2.0-0028025020&partnerID=MN8TOARS.
    10.1126/science.8073286
  19. Demengeot, J.; Jacquemier, J.; Torrente, M.; Blangy, D.; Berebbi, M.; Demengeot, J; Jacquemier, J; et al. "Pattern of polyomavirus replication from infection until tumor formation in the organs of athymic nu/nu mice". Journal of Virology 64 11 (1990): 5633-5639. http://www.scopus.com/inward/record.url?eid=2-s2.0-0025036314&partnerID=MN8TOARS.
    10.1128/jvi.64.11.5633-5639.1990
Preprint
  1. Iris Caramalho; Paula Matoso; Dário Ligeiro; Tiago Paixão; Daniel Sobral; Ana Laura Fitas; Catarina Limbert; Jocelyne Demengeot; Carlos Penha-Gonçalves. "The rare DRB1*04-DQ8 haplotype is the main discriminative HLA class II genetic driver of Early-Onset Type 1 Diabetes in the Portuguese population". 2023. https://doi.org/10.1101/2023.07.23.23293034.
    10.1101/2023.07.23.23293034
  2. F. Viana J; Bergman M; A. Gonçalves L; Duarte N; C. Borges P; Diwo C; Castro R; et al. "Population homogeneity for the antibody response to COVID-19 Comirnaty vaccine is only reached after the second dose". 2021. http://europepmc.org/abstract/PPR/PPR302374.
    10.1101/2021.03.19.21253680
Thesis / Dissertation
  1. "Robust tolerance out of versatile regulatory Tcells". PhD, Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, 2020.
  2. "Thymic activities in the establishment of tumor immune tolerance". PhD, Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, 2020.
  3. "Origin and function of regulatory T cells". PhD, Fundação da Faculdade de Ciências da Universidade de Lisboa, 2007.

Other

Other output
  1. Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 binding. 2021. Marta Alenquer; Filipe Ferreira; Diana Lousa; Mariana Valério; Mónica Medina-Lopes; Marie-Louise Bergman; Juliana Gonçalves; et al. https://doi.org/10.1101/2021.04.22.441007.
    10.1101/2021.04.22.441007
  2. Interruption of thymic activity in adults improves responses to tumor immunotherapy. 2020. José Almeida-Santos; Marie-Louise Bergman; Inês Amendoeira Cabral; Jocelyne Demengeot. https://doi.org/10.1101/2020.01.08.899484.
    10.1101/2020.01.08.899484
  3. A weak Foxp3 hypomorph enhances spontaneous and therapeutic immune surveillance of cancer in mice. 2019. José Almeida-Santos; Marie-Louise Bergman; Inês Amendoeira Cabral; Vasco Correia; Íris Caramalho; Jocelyne Demengeot. https://doi.org/10.1101/570671.
    10.1101/570671
Distinctions

Other distinction

2012 European Research Council panel member
European Research Council, Belgium